Alnylam Pharmaceuticals Inc., of Cambridge, Mass., said it has begun an underwritten public offering plus a concurrent private placement with Sanofi SA company Genzyme Corp., of Cambridge, Mass., which will buy enough shares directly from Alnylam to maintain its 12 percent ownership of the company.